Taking people in GermanyPhase 2
Tests tenecteplase given into the artery after clot removal in stroke
Tests extra clot-dissolving medicine given into the artery after clot removal in adults with stroke.
Key facts
- Who runs it
- Universitaetsklinikum Heidelberg AöR
- Where
- Aachen, Augsburg, Bielefeld, Bonn, Dortmund, Erfurt, Essen, Flensburg, Freiburg im Breisgau, Heidelberg, Ludwigsburg, Mainz, Minden, Nuremberg, and Wuerzburg, GermanySee the 15 sites
- Trial code
- Registry title
- Local Tenecteplase ApplicatiOn subsequent to endovasCular Recanalization in Anterior CircuLation Stroke - the LOCAL trial
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 380 people, planned
- Started
- 30 Mar 2026
- Expected to end
- 31 Jan 2029
- Type of study
- Interventional
- Record updated
- 8 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a sudden stroke caused by a blocked large artery in the front of the brain, whose artery was reopened successfully with a catheter procedure.
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- Acute ischemic stroke from a blocked large artery of the anterior circulation (distal ICA, Carotid-T, M1 or proximal M2), confirmed by CT or MRI and catheter angiography. Artery successfully reopened (eTICI≥ 2b50). Less than 24 hours since stroke onset or last seen well. NIHSS of 4 to 25 before the procedure. ASPECTS ≥ 6 on CT or ≥ 5 on diffusion weighted MRI.
- Earlier treatment
- Must have had mechanical recanalization (clot removal) with a successful result. Cannot have had intravenous rt-pA (alteplase) at the study site or intravenous TNK (tenecteplase) within 1 h before randomization.
Main reasons for not taking part
- Pre-stroke disability (before the stroke, mRS above 1)
- Bleeding in the brain now or before, or signs of it during the procedure
- Major surgery or severe bleeding in the past month
- Uncontrolled high blood pressure (SBP >185 mmHg or DBP >110 mmHg despite treatment)
- Pregnant or breast-feeding women
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- Patients with acute ischemic stroke due to large vessel occlusion of the anterior circulation (distal ICA, Carotid-T, M1 or proximal M2 occlusion) should be confirmed by either CT or MRI and must be proven by catheter angiographic run prior to mechanical recanalization
- Successful recanalization (eTICI≥ 2b50) of intracranial artery occlusion (as per definition by the interventionalist)
- Estimated time between stroke onset / last seen well and study procedure of < 24 hours
- No relevant pre-stroke functional disability (pre-morbid mRS of 0 – 1)
- Neurological deficit with a NIHSS of ≥ 4 and ≤ 25 at baseline prior to thrombectomy
- Age ≥ 18
- ASPECTS ≥ 6 on baseline non-contrast CT or ASPECTS ≥ 5 on diffusion weighted MRI
Who cannot take part
- Treatment with intravenous rt-pA (alteplase) thrombolysis at study site or intravenous TNK (tenecteplase) within 1 h before randomization
- Pre-existing stenosis in the target vessel requiring stent therapy
- Acute or prior intracranial hemorrhage or signs of intracranial hemorrhage during procedure
- Insufficient command of the German language, if this can be reliably determined prior to enrolment
- Hypersensitivity to the active substance (Tenecteplase), to any other excipients or to gentamicin or know allergy against alteplase
- Any efforts to control non-controlled hypertension after thrombectomy and before trial inclusion exceed 10 minutes
- Notably increased risk of intracranial hemorrhage
- Major surgery or any severe bleeding in the past month
- Non-controlled hypertension (defined as SBP >185 mmHg or DBP >110 mmHg refractory to treatment)
- Known severe illness with life expectancy less than 12 months
- Thrombocytopenia (Platelet count < 100,000)
- Participating in another clinical trial that could confound the treatment or outcomes of this investigation
- Tandem occlusions of both cervical and intracranial vessels
- Dissection of the extra- or intracranial cerebral arteries
- Pregnant or breast-feeding women
Where in Germany
- Universitaetsklinikum Aachen AöRAachen, GermanyTaking people
- Universitaetsklinikum AugsburgAugsburg, GermanyTaking people
- Evangelisches Klinikum Bethel gGmbHBielefeld, GermanyTaking people
- Universitaetsklinikum Bonn AöRBonn, GermanyTaking people
- Klinikum Dortmund gGmbHDortmund, GermanyTaking people
- HELIOS Klinikum Erfurt GmbHErfurt, GermanyTaking people
- Alfried Krupp Zentrum fuer Medizin und Rehabilitation gGmbHEssen, GermanyTaking people
- DIAKO Krankenhaus gGmbHFlensburg, GermanyTaking people
- Medical Center- University of FreiburgFreiburg im Breisgau, GermanyTaking people
- Universitaetsklinikum Heidelberg AöRHeidelberg, GermanyTaking people
- RKH Klinken Ludwigsburg-Bietigheim gGmbHLudwigsburg, GermanyTaking people
- Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöRMainz, GermanyTaking people
- Johannes Wesling Klinikum MindenMinden, GermanyTaking people
- Klinikum NuernbergNuremberg, GermanyTaking people
- Universitaetsklinikum Wuerzburg AöRWuerzburg, GermanyTaking people
About the trial
What the trial wants to find out
To investigate whether supplementary intra-arterial administration of thrombolysis (Tenecteplase) after successful endovascular recanalization of anterior circulation ischemic stroke results in improved clinical outcome evaluated based on the proportion of patients with an excellent clinical outcome of mRS 0 – 1 after 90 days +/- 15 days
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- Local tenecteplase applicatiOn subsequent to endovasCular recanalization in Anterior circuLation stroke - the LOCAL trial
- Plain-language title
- Tests tenecteplase given into the artery after clot removal in strokeGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 8 October 2026